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Abstract
Background: Despite recent improvements in the treatment of rheumatoid arthritis (RA), an insufficient treatment
response and the development of treatment resistance in many patients illustrates the need for new therapeutic
strategies. Chronic synovial inflammation could be suppressed by targeting RA synovial fibroblast (RASF) activation
by, for example, interleukin (IL)-17A-producing CCR6+ T helper memory (memTh) cells. Here, we modulated this
interaction by combining the active vitamin D metabolite 1,25(OH)2D3 with dexamethasone (DEX) and explored the
potential therapeutic applications.
Methods: CCR6+ memTh cells from peripheral blood mononuclear cells (PBMCs) of healthy donors or treatment-
naive early RA patients were cultured alone or with RASF from established RA patients for 3 days and treated with
or without 1,25(OH)2D3, DEX, or etanercept. Treatment effects were assessed using enzyme-linked immunosorbent
assay (ELISA) and flow cytometry.
Results: 1,25(OH)2D3, and to lesser extent DEX, reduced production of the pro-inflammatory cytokines IL-17A, IL-22,
and interferon (IFN)γ in CCR6+ memTh cells. Tumor necrosis factor (TNF)α was only inhibited by the combination of
1,25(OH)2D3 and DEX. In contrast, DEX was the strongest inhibitor of IL-6, IL-8, and tissue-destructive enzymes in
RASF. As a result, 1,25(OH)2D3 and DEX additively inhibited inflammatory mediators in CCR6
+ memTh-RASF cocultures.
Interestingly, low doses of mainly DEX, but also 1,25(OH)2D3, combined with etanercept better suppressed synovial
inflammation in this coculture model compared with etanercept alone.
Conclusion: This study suggests that 1,25(OH)2D3 and DEX additively inhibit synovial inflammation through targeting
predominantly CCR6+ memTh cells and RASF, respectively. Furthermore, low doses of DEX and 1,25(OH)2D3 enhance
the effect of TNFα blockade in inhibiting RASF activation, thus providing a basis to improve RA treatment.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory
autoimmune disease characterized by inflamed synovial
joints resulting in pain, fatigue, and disability in patients.
Although treatment has improved over the last decades,
many patients do not reach clinical remission, show
progressive joint damage, or become resistant to their
treatment [1]. Furthermore, the current therapies in-
clude the use of expensive biological disease-modifying
antirheumatic drugs (DMARDs) which pose a burden
on the healthcare budget. Therefore, there is still a need
to find new therapeutic options and to improve cur-
rently available treatments.
The main therapeutic goal in RA is to stop the chronic
synovial inflammation and thereby prevent the subsequent
cartilage and bone damage in the affected joint. Synovial
fibroblasts play an important role in this process since
they can secrete proinflammatory cytokines that attract
and activate immune cells, produce tissue-destructive
enzymes, and invade cartilage [2, 3]. How these RA
synovial fibroblasts (RASF) are activated is currently
unknown, although one of the hypotheses is that they are
activated by infiltrating immune cells. Previously we have
shown that CCR6+, but not CCR6–, memory T helper
(memTh) cells can activate RASF [4].
CCR6+ memTh cells are characterized by interleukin
(IL)-17A production and RAR-related orphan C receptor
(RORC) expression. This subset contains the classic
Th17 cells, but also contains, for example, Th17.1 cells
that produce high levels of interferon (IFN)γ [5]. Other
evidence that suggests a role for these IL-17A-producing
memTh cells is that Th17 cells and IL-17-mediated
signaling are required for the development of murine
autoimmune arthritis [6, 7]. Furthermore, CCR6+
memTh cells are more activated and more prevalent in
the blood of treatment-naive early RA patients and are
also found in the synovial fluid of RA patients [4, 8].
Upon interaction with CCR6+ memTh cells, RASF
secrete proinflammatory mediators such as IL-6, matrix
metalloproteases (MMPs), and prostaglandin E2 (PGE2)
via IL-17A and tumor necrosis factor (TNF)α. In turn,
these molecules, especially PGE2, further activate the
CCR6+ memTh cells to produce more IL-17A, thereby
creating a proinflammatory feedback loop that could drive
the chronic synovial inflammation [4, 9]. Therefore, inhi-
biting this proinflammatory loop may be beneficial in the
treatment of RA.
We have previously shown that combining the active
vitamin D metabolite 1,25(OH)2D3 with TNFα blockade,
a commonly used therapy in RA, additively suppresses
the proinflammatory loop between CCR6+ memTh and
RASF [10]. However, clinical translation of these findings
is challenging since high concentrations of 1,25(OH)2D3
were used. Interestingly, the effects of 1,25(OH)2D3 on
Th17-related cytokines, such as IL-17A, TNFα, and
IL-22, can be augmented through combination with
dexamethasone (DEX) [11]. DEX is a synthetic gluco-
corticoid (GC) which is clinically used for fast resolution
of inflammation and is often combined with vitamin D
supplements to prevent the osteoporotic side effects of
the drug [12].
Given the immunomodulatory capacities of both DEX
and 1,25(OH)2D3, we here investigated whether this
combination could suppress CCR6+ memTh cells, RASF,
and their interaction. Furthermore, the potential use of




Healthy control peripheral blood mononuclear cells
(PBMCs) were obtained from buffycoats (Sanquin,
Amsterdam, the Netherlands). For validation of findings
in healthy PBMCs, RA PBMCs were isolated from
treatment-naive RA patients who were embedded in the
tREACH study, which was ethically approved by the
METC Rotterdam. Relevant clinical information is sum-
marized in Additional file 1 (Table S1). RASF were
grown from synovial explants after joint replacement
surgery. All patients signed informed consent.
Cell sorting
PBMCs were isolated from peripheral blood using
ficoll-based cell separation and frozen in liquid nitrogen
until use. For sorting of CCR6+ memTh cells
(CD4+CD45RO+CCR6+CD25low/int), PBMCs were stained
using antibodies against CD4, CCR6, CD25 (BioLegend,
San Diego, CA, USA), and CD45RO (BD Biosciences, San
Diego, CA, USA). Before sorting CCR6+ memTh cells, the
cells were prepurified using CD4 microbeads via auto-
mated magnetic-activated cell sorting (Miltenyi Biotec,
Leiden, The Netherlands). Dead cells were excluded using
4′6-diamidino-2-phenylindole dilactate (DAPI) and
CCR6+ memTh cells were sorted on a FACSAriaIII sorter
(BD Biosciences).
Cell culture
RASF were obtained by culturing small synovial biopsies
in a culture flask with Dulbecco’s modified Eagle’s
medium (DMEM; Gibco, Waltham, MA, USA), supple-
mented with 10% fetal calf serum (FCS; Gibco) and
100 IU/ml penicillin/streptomycin (pen/strep; Lonza,
Verviers, Belgium). After RASF were grown out of the
synovial biopsies, cells were passaged and used for ex-
periments between passage 3 and 8. For coculture with
sorted T cells or stimulation experiments, RASF were
plated at a density of 1 × 104 cells/well in a 96-well plate
24 h before the T cells or stimulation medium were
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added. Where indicated, RASF were stimulated with
2 ng/ml recombinant TNFα and 5 ng/ml recombinant
IL-17A (R&D Systems, Minneapolis, MN, USA).
Sorted CCR6+ memTh cells were stimulated with
300 ng/ml soluble anti-CD3 and 400 ng/ml soluble
anti-CD28 (Sanquin, Amsterdam, the Netherlands) at a
density of 2.5 × 104 cells/ml in Iscove’s modified Dulbecco’s
medium (IMDM; Gibco) supplemented with 10% FCS,
100 IU/ml pen/strep, 2 mM L-glutamine, and 50 μM
β-mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA).
Cells were treated with or without 1,25(OH)2D3 (Leo
Pharmaceutical Products, Ballerup, Denmark), dexametha-
sone (Sigma-Aldrich), and etanercept (anti-TNFα, Pfizer,
New York, NY, USA) dissolved in 100% ethanol at the indi-
cated concentrations and added for the full duration of the
culture simultaneously with the stimulatory compounds.
Control conditions contained an equal volume of 100%
ethanol which never exceeded 0.1%.
Flow cytometry
Cultured cells were restimulated with 50 ng/ml phorbol
12-myristate 13 acetate (PMA), 500 ng/ml ionomycin
(Sigma-Aldrich), and GolgiStop (BD Biosciences) for 4 h.
Cells were then stained with Fixable Viability Dye eFluor506
(eBioscience, San Diego, CA, USA), fixated with 2% parafor-
maldehyde and permeabilized using 0.5% saponine. Intracel-
lular cytokines were stained with monoclonal antibodies
against IL-17A, IL-22 (eBioscience), and IFNγ (BioLegend).
Apoptosis was assessed using 7AAD/Annexin V staining,
performed according to the manufacturer’s instructions
(eBioscience). All samples were measured on the FACS-
CantoII Flow Cytometer (BD Biosciences).
Enzyme-linked immunosorbent assay (ELISA)
In culture supernatant after 3 days of culture, the concen-
tration of IL-17A, IL-22, IFNγ, TNFα, IL-10, IL-6, IL-8
(Ready-Set-Go, eBioscience), MMP1, MMP3 (DuoSet
ELISA, R&D Systems), and PGE2 (Prostaglandin E2 Par-
ameter Assay Kit, R&D Systems) were measured using
ELISA. The manufacturers’ protocols were followed.
Statistical analysis
Differences between experimental treatment groups were
tested using analysis of variance (ANOVA) with Bonferroni
post-hoc tests. p values below 0.05 were considered statisti-
cally significant. Analyses were performed using Prism soft-
ware version 6.01 (GraphPad Software, La Jolla, CA, USA).
Results
1,25(OH)2D3-DEX combination treatment suppresses TNFα
production from CCR6+ memTh cells
As a first step to examine the potential use of 1,25(OH)2D3
and DEX to inhibit synovial inflammation, CCR6+ memTh
cells were sorted from healthy controls and cultured for 3
days with 1,25(OH)2D3, DEX, or both. In line with the
previous studies, treatment with 1,25(OH)2D3 reduced the
percentage of cells producing IL-17A, IL-22, and IFNγ. On
the other hand, treatment with DEX did not affect the per-
centage of IL-22- or IFNγ-producing cells. The percentage
of IL-17A-producing cells was reduced by DEX, but signifi-
cantly less than by 1,25(OH)2D3. Combining 1,25(OH)2D3
and DEX had a similar effect as 1,25(OH)2D3 single treat-
ment (Fig. 1a, b). Notably, treatment with DEX significantly
reduced the amount of IL-17A and IFNγ that was produced
during the 3-day culture period (Fig. 1c). Since DEX is
known to induce cell death, the treatment effect on apop-
tosis was investigated. However, the minimal increase in
apoptosis on DEX or combination exposure could not ex-
plain the difference between flow cytometry and ELISA
(Additional file 1: Figure S1). Although no additive effect
was observed with 1,25(OH)2D3-DEX combination treat-
ment on IL-17A, IL-22, or IFNγ, TNFα was significantly
inhibited by the combined exposure (Fig. 1c). Since
1,25(OH)2D3 can induce an anti-inflammatory phenotype
in the CCR6+ memTh cells (Dankers et al., submitted
manuscript), the combinatory effects of 1,25(OH)2D3 and
DEX on IL-10 were also assessed. However, DEX did not
affect IL-10 production when used alone and reduced the
induction of IL-10 by 1,25(OH)2D3 when used in combin-
ation (Fig. 1c). Overall, these data show that 1,25(OH)2D3 is
the strongest modulator of IL-17A, IL-22, IFNγ, and IL-10
production by CCR6+ memTh cells, but the combination
of 1,25(OH)2D3 and DEX provides additional value through
enhanced TNFα inhibition.
1,25(OH)2D3 and DEX additively suppress the
proinflammatory feedback loop between CCR6+ memTh
cells and RASF
Since 1,25(OH)2D3 and DEX had additive effects in
blocking TNFα and they were both capable of reducing
the level of IL-17A that is produced by CCR6+ memTh
cells, we hypothesized that the combination treatment
would augment inhibition of the proinflammatory loop
between CCR6+ memTh cells and RASF when compared
with either compound alone. Similar to the effects of
1,25(OH)2D3 and DEX on CCR6
+ memTh cell cultures,
treatment of the CCR6+ memTh-RASF cocultures sig-
nificantly reduced IL-17A, IL-22, and IFNγ production,
especially with 1,25(OH)2D3. However, the production of
TNFα was stimulated upon treatment with DEX,
whereas it was still inhibited with the combination treat-
ment. Furthermore, IL-10 was significantly upregulated
in response to DEX and the combination of DEX and
1,25(OH)2D3, but not 1,25(OH)2D3 alone (Fig. 2).
Despite the differences in modulation of T cell-derived
cytokines by DEX and 1,25(OH)2D3, they equally inhibited
the RASF-derived factors IL-6, IL-8, and PGE2. For IL-6
and IL-8 there was also a trend towards additive inhibition
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in response to the combination of 1,25(OH)2D3 and DEX.
Interestingly, DEX treatment led to a significantly greater
inhibition of the tissue-destructive enzymes MMP1 and
MMP3 than 1,25(OH)2D3 treatment (Fig. 2). These data
suggest that, although no additive effect of 1,25(OH)2D3
and DEX is found on individual cytokines, the two com-
pounds cooperate to reduce the proinflammatory milieu at
an inflammatory synovial site by each targeting different
players in the inflammation. Furthermore, the increased
production of IL-10 potentially mediates anti-inflammatory
effects on other immune cells.
DEX is a stronger inhibitor of proinflammatory factors
from RASF than 1,25(OH)2D3
The finding that DEX is an equal inhibitor of IL-6 and
IL-8 and stronger inhibitor of MMP1 and MMP3 than
Fig. 1 1,25(OH)2D3 and DEX additively suppress proinflammatory cytokines secreted by CCR6
+ memTh cells. CCR6+ memTh cells were sorted
from healthy individuals and cultured for 3 days under stimulation with anti-CD3 and anti-CD28, with or without 100 nM 1,25(OH)2D3 and
1000 nM dexamethasone (DEX). a Representative flow cytometry plots of interleukin (IL)-17A-, IL-22-, and interferon (IFN)γ-producing cells. b
Quantification of flow cytometry as in a for six donors. c Cytokine production in the culture medium as measured by ELISA. Data show mean ±
SEM for n = 6–10 healthy individuals, representative of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
TNF tumor necrosis factor
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1,25(OH)2D3 while being less efficient in inhibiting T
cell-derived cytokines in the CCR6+ memTh-RASF
cocultures suggests a direct effect of DEX on RASF. To
investigate this, RASF were cultured with or without
stimulation of TNFα, IL-17A, or both for 3 days and
treated with 1,25(OH)2D3, DEX, or a combination
(Fig. 3). Without stimulation, 1,25(OH)2D3 did not signifi-
cantly affect cytokine production by RASF, whereas DEX
reduced the levels of IL-6 and IL-8. Upon stimulation with
TNFα, both 1,25(OH)2D3 and DEX inhibited IL-6 and
IL-8, whereas MMP1 and MMP3 were only significantly
inhibited by DEX or the combination treatment. Similar
patterns were observed with stimulation using IL-17A or
a combination of IL-17A and TNFα. Together with our
previous findings, these data suggest that, although DEX
and 1,25(OH)2D3 can affect both T cells and RASF, DEX
acts most strongly on RASF whereas the main effect of
1,25(OH)2D3 is mediated via the T cells.
Low dose of 1,25(OH)2D3 and DEX improves the effects of
TNFα blockade in CCR6+ memTh-RASF cocultures
Since 1,25(OH)2D3 and DEX additively inhibit the proin-
flammatory loop between CCR6+ memTh cells and
RASF, we next studied whether the 1,25(OH)2D3-DEX
combination can enhance the anti-inflammatory effect
of TNFα blockade in this model system. To make these
experiments more physiologically relevant, we used a
dose-testing experiment to determine whether physiolo-
gically relevant dosages of 1,25(OH)2D3 and DEX still af-
fected cytokine production in the CCR6+ memTh-RASF
Fig. 2 1,25(OH)2D3 and DEX additively suppress the proinflammatory feedback loop between CCR6
+ memTh cells and RASF. CCR6+ memTh
sorted from healthy individuals were cultured with RASF for 3 days. The cells were stimulated with anti-CD3 and anti-CD28 and treated with or
without 100 nM 1,25(OH)2D3 and 1000 nM dexamethasone (DEX). After 3 days, cytokine production was measured in the culture supernatant
using ELISA. Mean ± SEM are given for n = 10 healthy donors grown on RASF from two different donors. Data are representative of at least three
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. IFN interferon, IL interleukin, MMP matrix metalloprotease, PGE2
prostaglandin E2, TNF tumor necrosis factor
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coculture system; 10 nM DEX still inhibited IL-6, IL-8,
and MMP1 in CCR6+ memTh-RASF cocultures, but
0.1 nM 1,25(OH)2D3 only slightly affected these proin-
flammatory factors and did not appear different from
the 1 nM dose (Additional file 1: Figure S2). Therefore,
the value of adding DEX and 1,25(OH)2D3 to etanercept
was assessed using 10 nM DEX and 0.1 or 10 nM
1,25(OH)2D3. CCR6
+ memTh cells were sorted from
healthy controls and cultured together with RASF while
being exposed to various combinations of 1,25(OH)2D3,
DEX, and the TNFα-blocking agent etanercept. Inhi-
bition of IL-17A, IL-6, IL-8, MMP1, and MMP3 is
shown as heatmaps in Fig. 4 and further detailed in
Additional file 1 (Figure S3).
For IL-17A, etanercept dose-dependently inhibited
cytokine expression, but this effect was stronger (darker
shades) when the cells were also treated with 10 nM
1,25(OH)2D3. Combining DEX with this dose of
1,25(OH)2D3 further suppresses IL-17A and leaves little
added effect for etanercept. IL-6 and IL-8 are more
strongly inhibited by etanercept than IL-17A and show a
trend towards a dose response (left column of the heat-
map, top to bottom). Adding increasing dosages of
1,25(OH)2D3 augments the effects of etanercept, but the
optimal effect is reached when 10 nM DEX, 10 nM
1,25(OH)2D3, and etanercept are combined. Notably,
under these conditions there is no significant difference
between 0.1 or 10 μg/ml etanercept and cytokine expres-
sion is more than 90% reduced. MMP1 and MMP3 show
a similar pattern of inhibition as IL-6 and IL-8, except that
the effect of DEX is stronger even without additional
1,25(OH)2D3 or etanercept. These data suggest that com-
bining 1,25(OH)2D3 and especially DEX with etanercept
has additive effects compared with etanercept alone.
Since the cells from the healthy controls that were
used in Fig. 4 and Additional file 1 (Figure S3) may react
differently to treatment than the cells from RA patients,
the experiment was repeated using sorted CCR6+
memTh cells from treatment-naive early RA patients
cultured with RASF serving as a proof of principle (Fig. 5
and Additional file 1: Figure S4). Due to large variation
between patients (Additional file 1: Figure S4), there was
Fig. 3 DEX is a more potent inhibitor of cytokine production by stimulated and unstimulated RASF. RASF were left unstimulated or were
stimulated with tumor necrosis factor (TNF)α or interleukin (IL)-17A for 3 days and treated with or without 100 nM 1,25(OH)2D3 and 1000 nM
dexamethasone (DEX). Production of IL-6, IL-8, matrix metalloprotease (MMP)1 and MMP3 were measured after 3 days in the culture supernatant
using ELISA. Mean ± SEM are given for n = 6 RASF. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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a less clear dose-dependent inhibition of IL-17A in re-
sponse to etanercept. However, 10 nM 1,25(OH)2D3 still
enhanced the effects of etanercept, and IL-17A inhib-
ition was again further increased when 10 nM DEX was
added. The inhibition of IL-6 and IL-8 by etanercept was
stronger in the CCR6+ memTh cells from RA patients
than those from healthy individuals. Similar to the
results for the healthy controls, both 1,25(OH)2D3 and
DEX enhanced the effects of etanercept. MMP1 and
MMP3 were also inhibited by etanercept and their ex-
pression was further suppressed by DEX (Fig. 5).
Altogether, the data from Figs. 4 and 5 show that com-
bination with DEX, and to a lesser extent 1,25(OH)2D3,
provide a beneficial effect over TNFα blockade alone in
a model for synovial inflammation.
Discussion
This study showed that 1,25(OH)2D3 and DEX can addi-
tively inhibit synovial inflammation modeled by CCR6+
memTh-RASF cocultures. Furthermore, combining low
doses of DEX and 1,25(OH)2D3 with TNFα blockade
demonstrated added value over TNFα blockade alone.
Similar to our previous results in PBMCs and memTh
cells [11], 1,25(OH)2D3 was a stronger modulator of
IL-17A, IL-22, IFNγ, and IL-10 in CCR6+ memTh cells
than DEX. This could be due to the reported resistance
of CCR6+ memTh cells to cytokine inhibition and apop-
tosis induction by GCs [13]. Interestingly, in asthma, GC
resistance is increased with decreasing vitamin D serum
levels [14]. Since the vitamin D receptor can enhance
the activity of the GC receptor at promoter sites,
1,25(OH)2D3 may be able to overcome GC resistance
through this mechanism [15]. Notably, in Crohn’s
disease Th17.1 cells, one of the subpopulations within
CCR6+ memTh cells, are the most GC-resistant cells
[16]. Since these cells can also be found at the site of in-
flammation in juvenile idiopathic arthritis [17] and RA
(unpublished observations) further research into cell
type-specific modulation by GCs may further elucidate
its immunosuppressive actions in RA.
Fig. 4 Suppression of RASF activation by TNFα blockade is enhanced by adding DEX and 1,25(OH)2D3. CCR6+ memTh-RASF cocultures as
described in Fig. 2 were exposed to 10 nM dexamethasone (DEX), 0.1 or 10 nM 1,25(OH)2D3, and 0, 0.1, 1 or 10 μg/ml etanercept or
combinations of the compounds as indicated. After 3 days, synovial fibroblast activation was measured through cytokine detection using ELISA.
Arrows indicate increasing concentrations. Heatmaps are constructed using the mean inhibition in each condition of n = 6 healthy donors
cultured on RASF from two different RA patients. IL interleukin, MMP matrix metalloprotease
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Independent of the differences in modulation of cyto-
kines derived from CCR6+ memTh cells, either cultured
alone or together with RASF, both 1,25(OH)2D3 and
DEX inhibited the activation of synovial fibroblasts as
demonstrated by decreased IL-6, IL-8, MMP1, MMP3,
and PGE2. These data suggest that DEX has strong di-
rect effects on RASF, which was confirmed by
RASF-only cultures. Although others have shown that
1,25(OH)2D3 can inhibit MMP1 and MMP3 from RASF
under IL-1β stimulation [18], this was not observed in
our cultures with stimulation of TNFα and IL-17A.
Interestingly, whereas TNFα stimulation of RASF was
generally more potent than stimulation with IL-17A, the
combination of TNFα and IL-17A induced a higher level
of IL-6 and MMP1 and a striking stronger increase in
IL-8 and MMP3. It has been previously observed in kerati-
nocytes that IL-8 was more strongly induced by TNFα and
IL-17A than IL-6 [19]. Also, another study in RA
fibroblast-like synoviocytes suggested a slightly stronger
additive effect on IL-8 than IL-6, although they only used
1 ng/ml for both TNFα and IL-17A [20]. Since DEX and
1,25(OH)2D3 inhibit IL-8 and MMP3 both after TNFα
single stimulation or TNFα-IL-17A combination, this may
be an effective way to suppress even the strong stimulation
that is potentially present in the RA joint.
Based on other studies showing that the vitamin D
receptor and GC receptor can cooperate to enhance one
another’s functions [15, 21], we also expected synergistic
effects of 1,25(OH)2D3 and DEX in CCR6
+ memTh cells
or RASF. However, this synergy was not observed, except
that TNFα could only be inhibited when 1,25(OH)2D3 and
DEX were combined. Instead, the data indicate that
1,25(OH)2D3 and DEX additively suppress inflammation
through targeting different inflammatory pathways.
1,25(OH)2D3 indirectly reduces RASF activation through
modulation of IL-17A and could reduce activation of
other immune cells, such as macrophages, by inhibiting
IFNγ [22]. DEX, on the other hand, directly affects the
RASF and reduces immune cell activation, immune cell
attraction, and tissue destruction through regulation of
Fig. 5 Additive effects of dexamethasone (DEX) and 1,25(OH)2D3 on the inhibition of RASF activation by TNFα blockade are verified for
treatment-naive RA patients. Cocultures were set up as described in Fig. 4 using RASF from established RA patients and allogeneic CCR6+ memTh
cells sorted from PBMCs of treatment-naive early RA patients. Cytokine expression was measured using ELISA after 3 days of culture. Arrows
indicate increasing concentrations and heatmaps represent the mean inhibition per condition for n = 2–4 treatment-naive early RA patients. IL
interleukin, MMP matrix metalloprotease
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IL-6, IL-8, and MMPs, respectively. Finally, 1,25(OH)2D3
and DEX are both capable of inducing the
anti-inflammatory cytokine IL-10 in CCR6+ memTh cell
monocultures or in coculture with RASF, which could fur-
ther contribute to inhibiting synovial inflammation.
Because of the strong immunomodulatory effects of
1,25(OH)2D3 and DEX, we postulated that they could be
beneficial in the treatment of autoimmune diseases. This
study demonstrated that DEX especially could augment
the effect of TNFα blockade on RASF activation, even
up to the point that no differences could be seen between
the lowest and highest dose of anti-TNFα. Adding 0.1 nM
1,25(OH)2D3 did not contribute to this effect, but 10 nM
enhanced the effects of DEX and TNFα blockade. The
concentration of 0.1 nM (approximately 40 pg/ml) corre-
sponds to the 20–80 pg/ml of 1,25(OH)2D3 that has been
found in the synovial fluid of RA patients [23]. However,
the synovial fluid is not always a perfect representation of
the situation in the synovium. Furthermore, it has been re-
ported that immune cells are capable of converting
25(OH)D3 into 1,25(OH)2D3 [24, 25], suggesting that the
local concentration of active vitamin D in the inflamed
synovium may be higher than 0.1 nM and therefore could
contribute to the anti-inflammatory effects of DEX and
anti-TNFα.
Although these data indicate that a combination of
DEX and TNFα blockade could be beneficial in the
treatment of RA, some limitations of this study should
be considered. Firstly, the current study has focused on
an in-vitro culture model with only T cells and RASF,
whereas an inflamed joint also contains other cell types
[26]. Although 1,25(OH)2D3 and DEX are both known
for their wide range of immunomodulatory properties
[12, 27], the exact effects of combining these with TNFα
blockade have not been investigated. Furthermore, the
data suggest that dose reduction of TNFα blockade
could be possible on combination with DEX since there
is no dose-dependent effect anymore. It should be noted
that the physiological concentration of etanercept in the
synovial fluid has not been elaborately studied. One
study found the concentration of etanercept in the syn-
ovial fluid was around 20 ng/ml in two patients receiving
50 mg etanercept every 2 weeks after 5 weeks, thus in
between two dosages [28]. However, one patient who re-
ceived 50 mg every week had a concentration of 100 ng/
ml after 5 weeks, suggesting that the concentration
shortly after etanercept injection is in the range of the
0.1 μg/ml that was used in this study [28]. The inhibitory
effects of RASF activation by this dose of etanercept have
been drastically enhanced by DEX and 1,25(OH)2D3.
A final point to consider is that TNFα blockade has
more effects than only suppressing RASF activation [29].
Therefore, it is possible that our in-vitro model overlooks
interactions that may arise between the compounds and a
more complex environment. To study this, murine models
for RA, such as collagen-induced arthritis, could be used
as a first validation of our study. After that, a clinical trial
should be designed in which a low dose of DEX is
combined with TNFα blockade. Due to the perceived im-
munomodulatory effects of 1,25(OH)2D3, adding vitamin
D supplements to this treatment will not only prevent the
osteoporotic side effects of DEX, but it may also further
enhance the therapeutic effects.
Conclusion
This study suggests an added value of combining
1,25(OH)2D3 with DEX for inhibiting synovial inflamma-
tion in RA patients through their distinct cell type-specific
modulation properties. Furthermore, the findings in the
CCR6+ memTh-RASF functional coculture model provide
a rationale for a clinical trial combining low-dose
1,25(OH)2D3 and DEX with TNFα blockade to improve
disease management in RA.
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study. Figure S1. 1,25(OH)2D3 and DEX minimally affect apoptosis in
CCR6+ memTh cells. Figure S2. Low doses of 1,25(OH)2D3 and DEX still
modulate RASF activation by CCR6+ memTh cells. Figure S3. Complete
data behind the heatmaps of Fig. 4. Figure S4. Complete data behind
the heatmaps of Fig. 5. (DOCX 2328 kb)
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